Monte Rosa Therapeutics, Inc.
GLUE
$4.59
-$0.23-4.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.19M | 84.93M | 60.65M | 9.22M | 4.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.19M | 84.93M | 60.65M | 9.22M | 4.70M |
| Cost of Revenue | 29.05M | 30.11M | 36.76M | 25.52M | 25.67M |
| Gross Profit | -5.85M | 54.82M | 23.89M | -16.30M | -20.97M |
| SG&A Expenses | 9.70M | 10.78M | 10.88M | 10.23M | 11.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.75M | 40.89M | 47.64M | 35.74M | 37.34M |
| Operating Income | -15.55M | 44.04M | 13.00M | -26.53M | -32.64M |
| Income Before Tax | -11.10M | 47.71M | 15.60M | -23.79M | -30.06M |
| Income Tax Expenses | 1.20M | 822.00K | 2.16M | 71.00K | 252.00K |
| Earnings from Continuing Operations | -12.30M | 46.89M | 13.44M | -23.86M | -30.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.30M | 46.89M | 13.44M | -23.86M | -30.31M |
| EBIT | -15.55M | 44.04M | 13.00M | -26.53M | -32.64M |
| EBITDA | -13.43M | 46.08M | 15.07M | -24.42M | -30.58M |
| EPS Basic | -0.15 | 0.57 | 0.16 | -0.29 | -0.43 |
| Normalized Basic EPS | -0.08 | 0.36 | 0.12 | -0.18 | -0.26 |
| EPS Diluted | -0.15 | 0.57 | 0.16 | -0.29 | -0.43 |
| Normalized Diluted EPS | -0.08 | 0.36 | 0.12 | -0.18 | -0.26 |
| Average Basic Shares Outstanding | 82.19M | 82.15M | 82.12M | 82.01M | 71.23M |
| Average Diluted Shares Outstanding | 82.19M | 82.96M | 82.12M | 82.01M | 71.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |